NASDAQ:BDTX • US09203E1055
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BLACK DIAMOND THERAPEUTICS I (BDTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-17 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-04 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-10-16 | Stifel | Reiterate | Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-01 | Raymond James | Reiterate | Outperform |
| 2025-03-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | Stifel | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-07-31 | Raymond James | Initiate | Outperform |
| 2024-07-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 70M | -100.00% | 38.008M | 126.77M 233.54% | 304.07M 139.86% | 496.07M 63.14% | 670.86M 35.23% | |||||
| EBITDA YoY % growth | -86.023M 6.82% | -78.438M 8.82% | 20.195M 125.75% | -47.172M -333.58% | -52.717M -11.76% | -58.075M -10.16% | -64.882M -11.72% | 5.967M 109.20% | 103.34M 1,631.86% | 154.49M 49.50% | 192.04M 24.31% | |
| EBIT YoY % growth | -86.46M 6.86% | -78.781M 8.88% | 19.87M 125.22% | -49.83M -350.78% | -80.489M -61.53% | -80.411M 0.10% | -113.976M -41.74% | -38.566M 66.16% | 199.76M 617.97% | 356.64M 78.53% | 500.65M 40.38% | |
| Operating Margin | N/A | N/A | 28.39% | N/A | N/A | N/A | -299.87% | -30.42% | 65.70% | 71.89% | 74.63% | |
| EPS YoY % growth | -1.88 25.40% | -1.27 32.45% | 0.37 129.13% | -0.65 -275.09% | -0.96 -48.02% | -0.87 9.63% | -0.57 34.08% | -0.04 92.41% | 1.22 2,907.76% | 1.98 62.30% | 2.40 21.51% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 -119.23% | -0.20 -3.74% | -0.09 43.22% | -0.20 25.48% | -0.31 -65.09% | -0.34 -73.35% | -0.37 -331.14% | -0.40 -97.72% | -0.20 34.43% | -0.20 40.30% | -0.20 44.44% | -0.13 66.67% |
| Revenue Q2Q % growth | -100.00% | |||||||||||
| EBITDA Q2Q % growth | -11.288M -120.67% | -11.788M 11.02% | -11.927M -11.27% | -12.206M -22.83% | -12.862M -13.95% | -12.913M -9.55% | -12.883M -8.01% | -12.954M -6.13% | -13.28M -3.25% | -13.331M -3.24% | -13.311M -3.33% | -13.372M -3.23% |
| EBIT Q2Q % growth | -11.739M -121.53% | -12.566M 6.37% | -6.156M 43.93% | -14.495M -41.25% | -18.855M -60.62% | -20.4M -62.35% | -21.94M -256.41% | -23.486M -62.03% | -13.331M 29.29% | -13.362M 34.50% | -13.382M 39.01% | -13.413M 42.89% |
All data in USD
15 analysts have analysed BDTX and the average price target is 9.91 USD. This implies a price increase of 223.81% is expected in the next year compared to the current price of 3.06.
BLACK DIAMOND THERAPEUTICS I (BDTX) will report earnings on 2026-05-13.
The consensus EPS estimate for the next earnings of BLACK DIAMOND THERAPEUTICS I (BDTX) is -0.19 USD and the consensus revenue estimate is 0 USD.
The consensus rating for BLACK DIAMOND THERAPEUTICS I (BDTX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.